Evidence map›Paper›PMID 42243311›Full record

ArticleCommunications biology2026

Peptide occupancy governs HLA-E checkpoint interactions enabling VISTA recognition of destabilized HLA-E conformers.

Chelsae R Watters, Soroush Ghaffari, Carly Wilder, Michael Donkor, Gizem Oter, Katherine Upchurch-Ange, Susanne Gimlin, Niksa Kastrapeli, Jon Weidanz

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chelsae R WattersBoehringer Ingelheim Pharmaceuticals, Fort Worth, TX, USA.ORCID 0000-0001-6916-6509
Soroush GhaffariUniversity of Texas at Arlington, Arlington, TX, USA.ORCID 0000-0002-9744-6687
Carly WilderBoehringer Ingelheim Pharmaceuticals, Fort Worth, TX, USA.
Michael DonkorBoehringer Ingelheim Pharmaceuticals, Fort Worth, TX, USA.
Gizem OterBoehringer Ingelheim Pharmaceuticals, Fort Worth, TX, USA.
Katherine Upchurch-AngeBoehringer Ingelheim Pharmaceuticals, Fort Worth, TX, USA.
Susanne GimlinBoehringer Ingelheim Pharmaceuticals, Fort Worth, TX, USA.
Niksa KastrapeliBoehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
Jon WeidanzUniversity of Texas at Arlington, Arlington, TX, USA. Weidanz@uta.edu.ORCID 0000-0003-4455-9319

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human leukocyte antigen E (HLA-E) plays a central role in immune regulation across homeostasis, infection, cancer, and transplantation. Canonically, HLA-E presents leader sequence-derived VL9 peptides to engage CD94/NKG2 receptors, while alternative peptides disrupt this interaction. HLA-E also interacts with LILRB1/2 and the checkpoint molecule VISTA, but the role of peptide occupancy in these interactions remains unclear. Here, we demonstrate that HLA-E engages VISTA when peptide occupancy is absent or suboptimal, whereas interaction with LILRB1/2 is peptide independent. Both receptors recognize peptide-deficient or weakly stabilized HLA-E conformers. In contrast, stable peptide loading prevents VISTA binding, indicating that peptide occupancy governs receptor engagement. These findings support a model in which HLA-E exists along a spectrum of conformational states defined by peptide stability, enabling selective interaction with distinct immune checkpoints. This work identifies VISTA as a receptor for destabilized HLA-E conformers and reveals a previously unrecognized layer of immune regulation.

Indexed as

Histocompatibility Antigens Class IImmune Checkpoint ProteinsPeptidesAntigens, CDB7 AntigensHLA-E AntigensHumansLeukocyte Immunoglobulin-like Receptor B1Membrane GlycoproteinsProtein BindingReceptors, ImmunologicAntigens, CDB7 AntigensHistocompatibility Antigens Class IHLA-E AntigensImmune Checkpoint ProteinsLeukocyte Immunoglobulin-like Receptor B1LILRB1 protein, humanLILRB2 protein, humanMembrane GlycoproteinsPeptidesReceptors, ImmunologicVSIR protein, human

Identifiers

PMID42243311
PMCPMC13554117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.